Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 450

Sort by

Sort Order Select

Journal Articles

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Blood (2021) 138 (5): 387–400.

https://doi.org/10.1182/blood.2020008812

Published: 2021

Includes: Supplemental data

Journal Articles

von Willebrand disease: what does the future hold?

Cécile V. Denis, Sophie Susen, Peter J. Lenting

Blood (2021) 137 (17): 2299–2306.

https://doi.org/10.1182/blood.2020008501

Published: 2021

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Charlene C. Kabel, PharmD, Debra A. Goldman, MS, Larry W. Buie, PharmD, BCOP, FASHP, Virginia M. Klimek, MD

Blood (2019) 134 (Supplement_1): 1718.

https://doi.org/10.1182/blood-2019-129129

Published: 2019

Journal Articles

Patient-Reported Outcome Measures (PROMs) in Pediatric Non-Malignant Hematology: A Systematic Review

Robert J Klaassen, MD FRCPC, Julia Y. Kinahan, MDcal Student, Johann M. I. Graham, MDcal Student, Yamilée V. Hébert, MDcal Student, Katie O'Hearn, MSc Human Kinetics

Blood (2019) 134 (Supplement_1): 2180.

https://doi.org/10.1182/blood-2019-127248

Published: 2019

Journal Articles

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Robyn M. Scherber, MDMPH, Martin M. Goros, MS, Jonathan Gelfond, MD PhD, Amylou C. Dueck, PhD, Sarah F Christensen, MD, Hans Hasselbalch, MD, Holly L. Geyer, MD, Ruben A Mesa, MD

Blood (2019) 134 (Supplement_1): 2181.

https://doi.org/10.1182/blood-2019-126803

Published: 2019

Journal Articles

Multidisciplinary Implementation of an Iron Deficiency Anemia in Pregnancy Treatment Protocol

Pooja Mehra, MD, Surabhi Palkimas, PharmD, Laura Parsons, MD, Theresa Libby, RN, BSN, Leslie Ward, PharmD, Christian Chisholm, MD, Kelly Mercer Davidson, MD

Blood (2019) 134 (Supplement_1): 2121.

https://doi.org/10.1182/blood-2019-123902

Published: 2019

Journal Articles

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

David Cella, PhD, Jan McKendrick, Harrison Davis, Ravi Vij, MBBS, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2190.

https://doi.org/10.1182/blood-2019-122668

Published: 2019

Journal Articles

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Jakub Svoboda, MD, Philippe Armand, MD PhD, Fiona Taylor, Xiaowu Sun, Alejandro Moreno-Koehler, Srikanth Gajavelli, MD, Derek Peterson, Clara Chen, PhD BS, MS

Blood (2019) 134 (Supplement_1): 2192.

https://doi.org/10.1182/blood-2019-123980

Published: 2019

Journal Articles

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

Kendall H Sullivan, PharmD, Michael Toscani, PharmD, Tayla Poretta, PharmD, Ciera Patzke, PharmD, BCOP, Thushara Korattyil, PharmD, Denalee O'Malley, PhD MSW, Victor Gonzalez, MA, MS, Joseph Barone, PharmD, Andrew M. Evens, DO,MSc

Blood (2019) 134 (Supplement_1): 2134.

https://doi.org/10.1182/blood-2019-123459

Published: 2019

Journal Articles

The Effect of "Pathway" to Diagnosis for Childhood ITP on Caregiver Quality of Life at Time of Diagnosis

Michelle Neier, MD, Michele P. Lambert, MD, Rachael F. Grace, MD, Kerry Hege, MD, Stephanie Chiu, MPH, Julianne Thompson, Robert J Klaassen, MD FRCPC

Blood (2019) 134 (Supplement_1): 2174.

https://doi.org/10.1182/blood-2019-125686

Published: 2019

Journal Articles

Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes

Vivek Kumar, MD, M.B.,B.S., Mays F Abdulazeez, MBBS, Srilekha Bodepudi, Suman Biswas, Vivek Roy, MD, Taimur Sher, MD, Meghna Ailawadhi, MD, Victoria R. Alegria, Aneel Paulus, MD, Asher A. Chanan-Khan, MD, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 3494.

https://doi.org/10.1182/blood-2019-125888

Published: 2019

Journal Articles

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Thomas W. LeBlanc, MDMA,MHS, Roland B. Walter, MD PhD MS, Loriana Hernandez-Aldama, Kate Sully, PhD, Timothy J Bell, MHA, Chloe Johnson, Francois Peloquin, MSc, Adam Gater, Verna L Welch, PhD MPH, Louise O'Hara, Ryan Hohman, Diana Merino, Nigel H. Russell, MD, Neil Horikoshi, Dawn Maze, MDFRCPC,MSc

Blood (2019) 134 (Supplement_1): 3498.

https://doi.org/10.1182/blood-2019-124660

Published: 2019

Journal Articles

Quality of Life Was Not Negatively Impacted By the Addition of Lenalidomide to R-CHOP Chemotherapy (R 2 -CHOP) Compared with Placebo Plus R-CHOP Chemotherapy in Patients with Previously Untreated Activated B-Cell (ABC)-Type Diffuse Large B-Cell Lymphoma (DLBCL): Health-Related Quality of Life (HRQoL) Analysis of the International Robust Study

Blood (2019) 134 (Supplement_1): 3475.

https://doi.org/10.1182/blood-2019-123948

Published: 2019

Journal Articles

Quality of Life and Patient Reported Outcomes in Severe Chronic Neutropenia

Thomas F. Michniacki, MD, Lauren E. Merz, MDMSc, Harlan McCaffrey, MA MS, James A. Connelly, MD, Kelly J. Walkovich, MD

Blood (2019) 134 (Supplement_1): 3449.

https://doi.org/10.1182/blood-2019-126808

Published: 2019

Journal Articles

Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO

Pushpendra Goswami, PhD MSc, BPharm, Tatiana Ionova, DSc, Esther Natalie Oliva, PhD, Roger Else, Jonathan Kell, MD, Adele K. Fielding, MBBS,PhDFRCP,FRCPath, Daniel Jennings, Marina Karakantza, MD, Saad Al-Ismail, MD, Graham P. Collins, MA, MBBS, MRCP, FRCPath, DPhil, Stewart McConnell, Catherine Langton, Sam Salek, PhDRPh FFPM MCMS MRPSGB FESCP

Blood (2019) 134 (Supplement_1): 3484.

https://doi.org/10.1182/blood-2019-129030

Published: 2019

Journal Articles

Patient Reported Outcomes (PROs) Show Superior Quality of Life (QOL) of Patients with Chronic Myeloid Leukemia (CML) Treated with First Compared to Newer Generations of Tyrosine Kinase Inhibitors (TKIs)

Adi Shacham, MD, Lena Rosenman, Avi Leader, MD, Giora Sharf, Pia Raanani, MD, Uri Rozovski, MD

Blood (2019) 134 (Supplement_1): 4781.

https://doi.org/10.1182/blood-2019-129806

Published: 2019

Journal Articles

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Tatyana Ionova, PhD Professor, Tatiana Nikitina, PhD, Natalia Porfirieva, Anna Petrova, MD, Ekaterina Yu. Chelysheva, MD PhD, Oleg A. Shukhov, MD PhD, Anastasiya Bykova, MD, Galina Gusarova, MD PhD, Irina Nemchenko, MD PhD, Nikolay Tsyba, MD PhD, Anna G. Turkina, Prof., MD

Blood (2019) 134 (Supplement_1): 2925.

https://doi.org/10.1182/blood-2019-122041

Published: 2019

Journal Articles

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

Xin Ying Lee, Katarina Cepo, Thomas Porstmann

Blood (2019) 134 (Supplement_1): 2419.

https://doi.org/10.1182/blood-2019-122827

Published: 2019

Journal Articles

Assessing the Safety of Various VWF Regimens in Patients with Clinically Severe VWD: A Natural History Study

Robert F. Sidonio, Jr., MD MSc, Angela C. Weyand, MD, Dunlei Cheng, PhD, Crystal Watson

Blood (2019) 134 (Supplement_1): 1132.

https://doi.org/10.1182/blood-2019-128318

Published: 2019

NARROW

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

von Willebrand disease: what does the future hold?

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Choice of Hypomethylating Agent (HMA) for Initial Treatment Does Not Influence Outcome or Survival for Therapy-Related Myeloid Neoplasms (t-MN)

Patient-Reported Outcome Measures (PROMs) in Pediatric Non-Malignant Hematology: A Systematic Review

A Standardized Equation Model of Quality of Life in Myeloproliferative Neoplasms

Multidisciplinary Implementation of an Iron Deficiency Anemia in Pregnancy Treatment Protocol

Quality-of-Life Outcomes in Patients with Relapsed or Refractory Multiple Myeloma Treated with Elotuzumab Plus Lenalidomide/Dexamethasone or Lenalidomide/Dexamethasone: Final Analysis of the Phase 3 ELOQUENT-2 Study

Health-Related Quality-of-Life Outcomes in Patients with Classical Hodgkin Lymphoma: A Prospective, Observational Study in US Oncology Practices

Shared Decision Making in Cancer Treatment: Findings from a Large Survey of Lymphoma (LYM) Patients and Survivors

The Effect of "Pathway" to Diagnosis for Childhood ITP on Caregiver Quality of Life at Time of Diagnosis

Sociodemographic and Clinical Characteristics Associated with Patient's Decision to Refuse Multiple Myeloma (MM) Treatment, and Its Impact on Outcomes

Treatment Decision Making in AML: Factors of Importance to Clinicians, AML Patients and Their Family

Quality of Life and Patient Reported Outcomes in Severe Chronic Neutropenia

Final Development of the First Generic Quality of Life and Symptoms Measure Specific for Hematological Malignancies: The HM-PRO

Patient Reported Outcomes (PROs) Show Superior Quality of Life (QOL) of Patients with Chronic Myeloid Leukemia (CML) Treated with First Compared to Newer Generations of Tyrosine Kinase Inhibitors (TKIs)

The Impact of Comorbidity on Quality of Life in Chronic Myeloid Leukemia Patients with Deep Molecular Response Who Stopped Therapy By Tyrosine Kinase Inhibitors: Results of the RU-SKI Trial

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

Assessing the Safety of Various VWF Regimens in Patients with Clinically Severe VWD: A Natural History Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only